Incidences and hazard ratios for recurrent venous thrombosis
| . | Vitamin, N/py (ir %) . | Placebo, N/py (ir %) . | HR vitamin versus placebo* . |
|---|---|---|---|
| Intention-to-treat analysis | |||
| Hyperhomocysteinemic group | 26/387 (6.7) | 24/403 (6.0) | 1.14 (0.65-1.98) |
| Normohomocysteinemic group | 17/412 (4.1) | 26/373 (7.0) | 0.58 (0.32-1.08) |
| Overall | 43/799 (5.4) | 50/776 (6.4) | 0.84 (0.56-1.26) |
| On-treatment analysis | |||
| Hyperhomocysteinemic group | 24/338 (7.1) | 22/344 (6.4) | 1.13 (0.63-2.02) |
| Normohomocysteinemic group | 16/363 (4.4) | 22/337 (6.5) | 0.65 (0.34-1.24) |
| Overall | 40/702 (5.7) | 44/682 (6.4) | 0.88 (0.57-1.36) |
| Intention-to-treat analysis with exclusion of early recurrences† | |||
| Hyperhomocysteinemic group | 17/387 (4.4) | 21/403 (5.2) | 0.84 (0.44-1.60) |
| Normohomocysteinemic group | 15/412 (3.6) | 20/373 (5.4) | 0.66 (0.34-1.30) |
| Overall | 32/799 (4.0) | 41/776 (5.3) | 0.76 (0.48-1.21) |
| Intention-to-treat analysis beginning after cessation of anticoagulation | |||
| Hyperhomocysteinemic group | 23/338 (6.8) | 24/347 (6.9) | 0.98 (0.55-1.74) |
| Normohomocysteinemic group | 17/379 (4.5) | 24/338 (7.1) | 0.62 (0.33-1.15) |
| Overall | 40/717 (5.6) | 48/685 (7.0) | 0.80 (0.52-1.21) |
| . | Vitamin, N/py (ir %) . | Placebo, N/py (ir %) . | HR vitamin versus placebo* . |
|---|---|---|---|
| Intention-to-treat analysis | |||
| Hyperhomocysteinemic group | 26/387 (6.7) | 24/403 (6.0) | 1.14 (0.65-1.98) |
| Normohomocysteinemic group | 17/412 (4.1) | 26/373 (7.0) | 0.58 (0.32-1.08) |
| Overall | 43/799 (5.4) | 50/776 (6.4) | 0.84 (0.56-1.26) |
| On-treatment analysis | |||
| Hyperhomocysteinemic group | 24/338 (7.1) | 22/344 (6.4) | 1.13 (0.63-2.02) |
| Normohomocysteinemic group | 16/363 (4.4) | 22/337 (6.5) | 0.65 (0.34-1.24) |
| Overall | 40/702 (5.7) | 44/682 (6.4) | 0.88 (0.57-1.36) |
| Intention-to-treat analysis with exclusion of early recurrences† | |||
| Hyperhomocysteinemic group | 17/387 (4.4) | 21/403 (5.2) | 0.84 (0.44-1.60) |
| Normohomocysteinemic group | 15/412 (3.6) | 20/373 (5.4) | 0.66 (0.34-1.30) |
| Overall | 32/799 (4.0) | 41/776 (5.3) | 0.76 (0.48-1.21) |
| Intention-to-treat analysis beginning after cessation of anticoagulation | |||
| Hyperhomocysteinemic group | 23/338 (6.8) | 24/347 (6.9) | 0.98 (0.55-1.74) |
| Normohomocysteinemic group | 17/379 (4.5) | 24/338 (7.1) | 0.62 (0.33-1.15) |
| Overall | 40/717 (5.6) | 48/685 (7.0) | 0.80 (0.52-1.21) |